CoChat

PGRN acts as a novel regulator of mitochondrial homeostasis by facilitating mitophagy and mitochondrial biogenesis to prevent podocyte injury in diabetic nephropathy

Open access

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Abstract

Mitochondrial dysfunction is considered as a key mediator in the pathogenesis of diabetic nephropathy (DN). Therapeutic strategies targeting mitochondrial dysfunction hold considerable promise for the treatment of DN. In this study, we investigated the role of progranulin (PGRN), a secreted glycoprotein, in mediating mitochondrial homeostasis and its therapeutic potential in DN. We found that the level of PGRN was significantly reduced in the kidney from STZ-induced diabetic mice and patients with biopsy-proven DN compared with healthy controls. In DN model, PGRN-deficient mice aggravated podocyte injury and proteinuria versus wild-type mice. Functionally, PGRN deficiency exacerbated mitochondrial damage and dysfunction in podocytes from diabetic mice. In vitro, treatment with recombinant human PGRN (rPGRN) attenuated high glucose-induced mitochondrial dysfunction in podocytes accompanied by enhanced mitochondrial biogenesis and mitophagy. Inhibition of mitophagy disturbed the protective effects of PGRN in high glucose-induced podocytotoxicity. Mechanistically, we demonstrated that PGRN maintained mitochondrial homeostasis via PGRN-Sirt1-PGC-1α/FoxO1 signaling-mediated mitochondrial biogenesis and mitophagy. Finally, we provided direct evidence for therapeutic potential of PGRN in mice with DN. This study provides new insights into the novel role of PGRN in maintaining mitochondrial homeostasis, suggesting that PGRN may be an innovative therapeutic strategy for treating patients with DN.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-019-1754-3

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The level of PGRN was significantly reduced in the kidney under diabetic conditions. a Representative photomicrographs and semiquantitation of PGRN immunohistochemical staining in human renal cortical tissue from normal subjects (n = 8), patients with diabetic nephropathy (DN) (n = 8), or diabetic patients without nephropathy (DM-NN) (n = 7). *P < 0.05 vs. Normal, #P < 0.05 vs. DM-NN. b Representative photomicrographs of PGRN immunohistochemical staining in the kidney from wild-type (WT) and PGRN-deficient (Grn−/−) mice (n = 6). Negative control by omission of the corresponding primary antibodies demonstrated no nonspecific staining. c Representative western blot gel documents and summarized data showing the relative protein levels of PGRN in human podocytes treated with high glucose (HG, final concentration 20 or 40 mmol/l in medium) for 48 h. *P < 0.05 vs. NG treatment. d Representative confocal microscopic images showing the expression of PGRN in podocytes of kidney from STZ-induced diabetic mice (n = 6), synaptopodin was used as a podocytes marker. The arrows indicate representative podocytes
Fig. 1 The level of PGRN was significantly reduced in the kidney under diabetic conditions. a Representative photomicrographs and semiquantitation of PGRN immunohistochemical staining in human renal cortical tissue from normal subjects (n = 8), patients with diabetic nephropathy (DN) (n = 8), or diabetic patients without nephropathy (DM-NN) (n = 7). *P < 0.05 vs. Normal, #P < 0.05 vs. DM-NN. b Representative photomicrographs of PGRN immunohistochemical staining in the kidney from wild-type (WT) and PGRN-deficient (Grn−/−) mice (n = 6). Negative control by omission of the corresponding primary antibodies demonstrated no nonspecific staining. c Representative western blot gel documents and summarized data showing the relative protein levels of PGRN in human podocytes treated with high glucose (HG, final concentration 20 or 40 mmol/l in medium) for 48 h. *P < 0.05 vs. NG treatment. d Representative confocal microscopic images showing the expression of PGRN in podocytes of kidney from STZ-induced diabetic mice (n = 6), synaptopodin was used as a podocytes marker. The arrows indicate representative podocytesCC BY · PubMed Central
Fig. 2 PGRN deficiency exacerbated podocyte injury and proteinuria in DN. a Urine albumin-to-creatinine ratio (UACR) in different groups of mice. b Representative images of periodic-acid-Schiff (PAS) staining of kidney sections in different groups of mice. c Quantification of Mesangial Matrix Index of glomerulus from different groups of mice. d Representative transmission electron microscopy (TEM) images showing morphological changes in the podocyte foot process in different groups of mice. e Quantitative assessment of glomerular filtration barrier integrity, including glomerular basement membrane (GBM) thickness, foot process width and the number of foot processes/μm GBM. *P < 0.05 vs. sham-operated mice, #P < 0.05 vs. WT diabetic mice (n = 6). f Representative microscopic images showing the expressions of podocin and nephrin in the kidney from different groups of mice
Fig. 2 PGRN deficiency exacerbated podocyte injury and proteinuria in DN. a Urine albumin-to-creatinine ratio (UACR) in different groups of mice. b Representative images of periodic-acid-Schiff (PAS) staining of kidney sections in different groups of mice. c Quantification of Mesangial Matrix Index of glomerulus from different groups of mice. d Representative transmission electron microscopy (TEM) images showing morphological changes in the podocyte foot process in different groups of mice. e Quantitative assessment of glomerular filtration barrier integrity, including glomerular basement membrane (GBM) thickness, foot process width and the number of foot processes/μm GBM. *P < 0.05 vs. sham-operated mice, #P < 0.05 vs. WT diabetic mice (n = 6). f Representative microscopic images showing the expressions of podocin and nephrin in the kidney from different groups of miceCC BY · PubMed Central
Fig. 3 The cell death and mitochondrial damage were further exacerbated in podocytes of Grn−/− diabetic mice. a In situ terminal deoxynucleotidyl transferase-mediated UTP nick-end labeling (TUNEL) assays were performed to assess the cell death in glomerulus. Nuclei were revealed using 4′,6-diamidino-2-phenylindole (DAPI) staining. Quantitative assessment of the number of cell death (number of TUNEL-positive cells per glomerulus). b Double immunofluorescence staining for cleaved-caspase 3 (green) and synaptopodin (red) in the kidney from different groups of mice. Quantitative assessment of the number of cleaved-caspase 3-positive podocytes in glomerulus. c Representative TEM images of glomeruli demonstrating mitochondrial morphology in podocytes of kidney sections and quantification of percentage of altered mitochondria characterized by mitochondria swelling, vacuolization and cristae fragmentation in podocytes from different groups of mice. Red arrows indicate representative mitochondria. d Representative photomicrographs and semiquantitation of cytochrome C oxidase (complex IV) subunit IV isoform 1 (COXIV) immunohistochemical staining in the kidney from different groups of mice. *P < 0.05 vs. sham-operated mice, #P < 0.05 vs. WT diabetic mice (n = 6)
Fig. 3 The cell death and mitochondrial damage were further exacerbated in podocytes of Grn−/− diabetic mice. a In situ terminal deoxynucleotidyl transferase-mediated UTP nick-end labeling (TUNEL) assays were performed to assess the cell death in glomerulus. Nuclei were revealed using 4′,6-diamidino-2-phenylindole (DAPI) staining. Quantitative assessment of the number of cell death (number of TUNEL-positive cells per glomerulus). b Double immunofluorescence staining for cleaved-caspase 3 (green) and synaptopodin (red) in the kidney from different groups of mice. Quantitative assessment of the number of cleaved-caspase 3-positive podocytes in glomerulus. c Representative TEM images of glomeruli demonstrating mitochondrial morphology in podocytes of kidney sections and quantification of percentage of altered mitochondria characterized by mitochondria swelling, vacuolization and cristae fragmentation in podocytes from different groups of mice. Red arrows indicate representative mitochondria. d Representative photomicrographs and semiquantitation of cytochrome C oxidase (complex IV) subunit IV isoform 1 (COXIV) immunohistochemical staining in the kidney from different groups of mice. *P < 0.05 vs. sham-operated mice, #P < 0.05 vs. WT diabetic mice (n = 6)CC BY · PubMed Central
Fig. 4 PGRN protected against HG-induced mitochondrial damage and dysfunction, and restored HG-reduced mitochondrial biogenesis in podocytes. a Representative images for MitoTracker green staining showing mitochondrial morphology and quantification of mitochondrial length in live cultured podocytes with different treatments. The results were normalized to the mitochondrial length of NG-treated podocytes. b Representative TEM images showing mitochondrial morphology and quantification of the percentage of altered mitochondria and mitochondria diameter of live cultured podocytes with different treatments. c Representative images of podocytes stained with JC-1 and quantification of JC-1 fluorescence (red-to-green ratio) showing changes in fluorescence intensity in podocytes with different treatments. JC-1 fluorescence was normalized with the red-to-green ratio of NG-treated podocytes. d Relative mitochondrial DNA content (mtDNA:nDNA) in podocytes with different treatments. The results were normalized to the ratio of mtDNA:nDNA of NG-treated podocytes. e Representative western blot gel documents and summarized data showing the expression levels of PGC-1α and TFAM in podocytes with different treatments. *P < 0.05 vs. NG treatment, #P < 0.05 vs. HG treatment
Fig. 4 PGRN protected against HG-induced mitochondrial damage and dysfunction, and restored HG-reduced mitochondrial biogenesis in podocytes. a Representative images for MitoTracker green staining showing mitochondrial morphology and quantification of mitochondrial length in live cultured podocytes with different treatments. The results were normalized to the mitochondrial length of NG-treated podocytes. b Representative TEM images showing mitochondrial morphology and quantification of the percentage of altered mitochondria and mitochondria diameter of live cultured podocytes with different treatments. c Representative images of podocytes stained with JC-1 and quantification of JC-1 fluorescence (red-to-green ratio) showing changes in fluorescence intensity in podocytes with different treatments. JC-1 fluorescence was normalized with the red-to-green ratio of NG-treated podocytes. d Relative mitochondrial DNA content (mtDNA:nDNA) in podocytes with different treatments. The results were normalized to the ratio of mtDNA:nDNA of NG-treated podocytes. e Representative western blot gel documents and summarized data showing the expression levels of PGC-1α and TFAM in podocytes with different treatments. *P < 0.05 vs. NG treatment, #P < 0.05 vs. HG treatmentCC BY · PubMed Central
Fig. 5 PGRN rescued HG-reduced mitophagy in podocytes. a Representative western blot gel documents and summarized data showing the protein levels of PARK2 in kidney from different groups of mice. *P < 0.05 vs. sham-operated mice, #P < 0.05 vs. WT diabetic mice (n = 6). b Representative western blot gel documents and summarized data showing the relative protein levels of PINK1 and PARK2 in podocytes with different treatments. c Representative confocal microscopic images of double immunofluorescence staining for TOMM20 (green) and LC3 (red) in podocytes with different treatments. Nuclei were revealed using DAPI staining. White arrows indicate colocalization of autophagosomes (LC3) and mitochondria (TOMM20). d Quantitative analysis of mitophagosome formation represented by colocalization of autophagosomes (LC3) and mitochondria (TOMM20). e Representative TEM images demonstrating mitophagosomes (mitophagosomes engulfing mitochondria) in podocytes with different treatments. Red arrows indicate representative mitophagosomes. f Quantification of the numbers of mitophagic vacuoles of each group. *P < 0.05 vs. NG treatment, #P < 0.05 vs. HG treatment. g Representative western blot gel documents and summarized data showing the relative protein level of PARK2 in siRNA-NC or siRNA-PARK2-transfected podocytes. *P < 0.05 vs. siRNA-NC. h Representative western blot gel documents and summarized data showing the expression levels of cleaved-PARP1 in podocytes with different treatments. i Representative flow cytometry analysis depicting the detection of apoptosis in podocytes with different treatments stained with fluorescein isothiocyanate (FITC)-conjugated Annexin V and propidium iodide (PI). j Quantitative data expressing overall percentage of cell death (annexin V-FITC-positive), including the amount of apoptotic and necrotic cells determined by flow cytometric analysis in podocytes with different treatments. *P < 0.05 vs. NG + siRNA-NC, #P < 0.05 vs. HG + siRNA-NC, §P < 0.05 vs. HG + rPGRN + siRNA-NC
Fig. 5 PGRN rescued HG-reduced mitophagy in podocytes. a Representative western blot gel documents and summarized data showing the protein levels of PARK2 in kidney from different groups of mice. *P < 0.05 vs. sham-operated mice, #P < 0.05 vs. WT diabetic mice (n = 6). b Representative western blot gel documents and summarized data showing the relative protein levels of PINK1 and PARK2 in podocytes with different treatments. c Representative confocal microscopic images of double immunofluorescence staining for TOMM20 (green) and LC3 (red) in podocytes with different treatments. Nuclei were revealed using DAPI staining. White arrows indicate colocalization of autophagosomes (LC3) and mitochondria (TOMM20). d Quantitative analysis of mitophagosome formation represented by colocalization of autophagosomes (LC3) and mitochondria (TOMM20). e Representative TEM images demonstrating mitophagosomes (mitophagosomes engulfing mitochondria) in podocytes with different treatments. Red arrows indicate representative mitophagosomes. f Quantification of the numbers of mitophagic vacuoles of each group. *P < 0.05 vs. NG treatment, #P < 0.05 vs. HG treatment. g Representative western blot gel documents and summarized data showing the relative protein level of PARK2 in siRNA-NC or siRNA-PARK2-transfected podocytes. *P < 0.05 vs. siRNA-NC. h Representative western blot gel documents and summarized data showing the expression levels of cleaved-PARP1 in podocytes with different treatments. i Representative flow cytometry analysis depicting the detection of apoptosis in podocytes with different treatments stained with fluorescein isothiocyanate (FITC)-conjugated Annexin V and propidium iodide (PI). j Quantitative data expressing overall percentage of cell death (annexin V-FITC-positive), including the amount of apoptotic and necrotic cells determined by flow cytometric analysis in podocytes with different treatments. *P < 0.05 vs. NG + siRNA-NC, #P < 0.05 vs. HG + siRNA-NC, §P < 0.05 vs. HG + rPGRN + siRNA-NCCC BY · PubMed Central
Fig. 6 PGRN activated Sirt1-PGC-1α/FoxO1 pathway in HG-treated podocytes. a Representative western blot gel documents of Sirts in podocytes with different treatments. b Summarized data showing the expression levels of Sirts in podocytes with different treatments. *P < 0.05 vs. NG treatment, #P < 0.05 vs. HG treatment. c Representative western blot gel documents and summarized data showing the expression levels of Sirt1 in kidney from different groups of mice. *P < 0.05 vs. sham-operated mice, #P < 0.05 vs. WT diabetic mice (n = 6). d Representative western blot gel documents and summarized data showing the levels of acetylated-FoxO1 in podocytes with different treatments. e Representative western blot gel documents and summarized data showing the levels of acetylated-PGC-1α in podocytes with different treatments. The acetylated proteins were immunoprecipitated with an antibody to acetylated lysine and the presence of PGC-1α in the immune-complex was assessed by western blot with the antibody to PGC-1α. f Relative mRNA levels of PGC-1α, TFAM, PINK1, and PARK2 in podocytes with different treatments. *P < 0.05 vs. NG treatment, #P < 0.05 vs. HG treatment
Fig. 6 PGRN activated Sirt1-PGC-1α/FoxO1 pathway in HG-treated podocytes. a Representative western blot gel documents of Sirts in podocytes with different treatments. b Summarized data showing the expression levels of Sirts in podocytes with different treatments. *P < 0.05 vs. NG treatment, #P < 0.05 vs. HG treatment. c Representative western blot gel documents and summarized data showing the expression levels of Sirt1 in kidney from different groups of mice. *P < 0.05 vs. sham-operated mice, #P < 0.05 vs. WT diabetic mice (n = 6). d Representative western blot gel documents and summarized data showing the levels of acetylated-FoxO1 in podocytes with different treatments. e Representative western blot gel documents and summarized data showing the levels of acetylated-PGC-1α in podocytes with different treatments. The acetylated proteins were immunoprecipitated with an antibody to acetylated lysine and the presence of PGC-1α in the immune-complex was assessed by western blot with the antibody to PGC-1α. f Relative mRNA levels of PGC-1α, TFAM, PINK1, and PARK2 in podocytes with different treatments. *P < 0.05 vs. NG treatment, #P < 0.05 vs. HG treatmentCC BY · PubMed Central
Fig. 7 Inhibition of Sirt1 expression counteracted the protective effects of PGRN in podocytes with HG treatment. a Representative western blot gel documents of acetylated-FoxO1, FoxO1, PINK1, and PARK2 in podocytes with different treatments. b Representative western blot gel documents of acetylated-PGC-1α and PGC-1α in podocytes with different treatments. c Summarized data showing the levels of acetylated-FoxO1 and acetylated-PGC-1α relative to FoxO1 and PGC-1α, and the expression levels of PINK1, PARK2, and PGC-1α in podocytes with different treatments. d Representative confocal microscopic images of double immunofluorescence staining for TOMM20 (green) and LC3 (red) in podocytes with different treatments. Nuclei were revealed using DAPI staining. e Quantitative analysis of mitophagosome formation represented by colocalization of autophagosomes (LC3) and mitochondria (TOMM20). f Relative mitochondrial DNA content (mtDNA:nDNA) in podocytes with different treatments. The results were normalized to the ratio of mtDNA:nDNA of NG-treated podocytes with siRNA-NC transfection. g Representative images of podocytes stained with JC-1 in live cultured podocytes with different treatments. h Quantification of JC-1 fluorescence (red-to-green ratio) showing changes in fluorescence intensity in podocytes with different treatments. JC-1 fluorescence was normalized with the red-to-green ratio of NG-treated podocytes with siRNA-NC transfection. i Representative flow cytometry analysis depicting the detection of apoptosis in podocytes with different treatments stained with fluorescein isothiocyanate (FITC)-conjugated Annexin V and propidium iodide (PI). j Quantitative data expressing overall percentage of cell death (annexin V-FITC-positive), including the amount of apoptotic and necrotic cells determined by flow cytometric analysis in podocytes with different treatments. *P < 0.05 vs. NG treatment, #P < 0.05 vs. HG treatment, §P < 0.05 vs. siRNA-NC
Fig. 7 Inhibition of Sirt1 expression counteracted the protective effects of PGRN in podocytes with HG treatment. a Representative western blot gel documents of acetylated-FoxO1, FoxO1, PINK1, and PARK2 in podocytes with different treatments. b Representative western blot gel documents of acetylated-PGC-1α and PGC-1α in podocytes with different treatments. c Summarized data showing the levels of acetylated-FoxO1 and acetylated-PGC-1α relative to FoxO1 and PGC-1α, and the expression levels of PINK1, PARK2, and PGC-1α in podocytes with different treatments. d Representative confocal microscopic images of double immunofluorescence staining for TOMM20 (green) and LC3 (red) in podocytes with different treatments. Nuclei were revealed using DAPI staining. e Quantitative analysis of mitophagosome formation represented by colocalization of autophagosomes (LC3) and mitochondria (TOMM20). f Relative mitochondrial DNA content (mtDNA:nDNA) in podocytes with different treatments. The results were normalized to the ratio of mtDNA:nDNA of NG-treated podocytes with siRNA-NC transfection. g Representative images of podocytes stained with JC-1 in live cultured podocytes with different treatments. h Quantification of JC-1 fluorescence (red-to-green ratio) showing changes in fluorescence intensity in podocytes with different treatments. JC-1 fluorescence was normalized with the red-to-green ratio of NG-treated podocytes with siRNA-NC transfection. i Representative flow cytometry analysis depicting the detection of apoptosis in podocytes with different treatments stained with fluorescein isothiocyanate (FITC)-conjugated Annexin V and propidium iodide (PI). j Quantitative data expressing overall percentage of cell death (annexin V-FITC-positive), including the amount of apoptotic and necrotic cells determined by flow cytometric analysis in podocytes with different treatments. *P < 0.05 vs. NG treatment, #P < 0.05 vs. HG treatment, §P < 0.05 vs. siRNA-NCCC BY · PubMed Central
Fig. 8 Administration of recombinant human PGRN (rPGRN) protected against podocyte injury in mice with DN. a A representative figure showing the procedure of rPGRN treatment in this study. b Urine albumin-to-creatinine ratio (UACR) in different groups of mice. c Representative images of PAS staining of kidney sections in different groups of mice. d Quantification of Mesangial Matrix Index of glomerulus from different groups of mice. e Representative TEM images showing morphological changes in the podocyte foot process in different groups of mice. Quantitative assessment of glomerular filtration barrier integrity, including GBM thickness and the number of foot processes/μm GBM. f In situ TUNEL assays were performed to assess the cell death in glomerulus from different groups of mice. Nuclei were revealed using DAPI staining. Quantitative assessment of the number of cell death (number of TUNEL-positive cells per glomerulus). g Representative TEM images of glomeruli demonstrating mitochondrial morphology in podocytes of kidney sections. Quantification of the percentage of altered mitochondria in podocytes from different groups of mice. h Representative western blot gel documents and summarized data showing the expression levels of Sirt1, PGC-1α, and PINK2 in kidney from different groups of mice. *P < 0.05 vs. sham-operated mice, #P < 0.05 vs. WT diabetic mice (n = 6). i Representative photomicrographs of PINK1 immunohistochemical staining in the kidney from different groups of mice. j Schematic representation showing that PGRN plays an important role in maintaining mitochondrial homeostasis to prevent podocyte injury in diabetic nephropathy by regulating Sirt1-PGC-1α/FoxO1 signaling-mediated mitochondrial biogenesis and mitophagy
Fig. 8 Administration of recombinant human PGRN (rPGRN) protected against podocyte injury in mice with DN. a A representative figure showing the procedure of rPGRN treatment in this study. b Urine albumin-to-creatinine ratio (UACR) in different groups of mice. c Representative images of PAS staining of kidney sections in different groups of mice. d Quantification of Mesangial Matrix Index of glomerulus from different groups of mice. e Representative TEM images showing morphological changes in the podocyte foot process in different groups of mice. Quantitative assessment of glomerular filtration barrier integrity, including GBM thickness and the number of foot processes/μm GBM. f In situ TUNEL assays were performed to assess the cell death in glomerulus from different groups of mice. Nuclei were revealed using DAPI staining. Quantitative assessment of the number of cell death (number of TUNEL-positive cells per glomerulus). g Representative TEM images of glomeruli demonstrating mitochondrial morphology in podocytes of kidney sections. Quantification of the percentage of altered mitochondria in podocytes from different groups of mice. h Representative western blot gel documents and summarized data showing the expression levels of Sirt1, PGC-1α, and PINK2 in kidney from different groups of mice. *P < 0.05 vs. sham-operated mice, #P < 0.05 vs. WT diabetic mice (n = 6). i Representative photomicrographs of PINK1 immunohistochemical staining in the kidney from different groups of mice. j Schematic representation showing that PGRN plays an important role in maintaining mitochondrial homeostasis to prevent podocyte injury in diabetic nephropathy by regulating Sirt1-PGC-1α/FoxO1 signaling-mediated mitochondrial biogenesis and mitophagyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 172

Metadata

Authors
Zhou, D., Zhou, M., Wang, Z., Fu, Y., Jia, M., Wang, X., Liu, M., Zhang, Y., Sun, Y., Lu, Y., Tang, W., & Yi, F.
Affiliations
Shandong University (CN)
Corresponding author
  • Tang, Wei
  • Yi, Fan
Venue
Cell Death & Disease
Published
2019-07-08
Volume
10
Issue
7
Pages
524-524
ISSN
2041-4889 (ISSN-L)
OpenAlex
W2976176026
Cited by
162
References
48
Citations by year
2026: 10 · 2025: 29 · 2024: 24 · 2023: 32 · 2022: 31 · 2021: 20 · 2020: 16
FWCI
12.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (81600570, 81873614, 81470958, 81770726, 81700636, 91642204, 81525005, 81670629)
  • Natural Science Foundation of Shandong Province (ZR2016HM03)
  • China National Funds for Distinguished Young Scientists
Topics
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
progranulin, diabetic nephropathy, podocyte injury, mitochondrial homeostasis, mitophagy, mitochondrial biogenesis, mitochondrial dysfunction, SIRT1, PGC-1α, FOXO1, proteinuria, high glucose
MeSH terms
Forkhead Box Protein O1, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Progranulins, Acetylation, Animals, Organelle Biogenesis, Biopsy, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Glucose, Homeostasis, Humans, Kidney, Mice, Inbred C57BL, Mitochondria, Cell Death, Cytoprotection, Podocytes, Rats, Sirtuin 1, Mitophagy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PGRN acts as a novel regulator of mitochondrial homeostasis by facilitating mitophagy and mitochondrial biogenesis to prevent podocyte injury in diabetic nephropathy. https://app.cochat.ai/papers/10.1038/s41419-019-1754-3
The paper
Zhou, D., Zhou, M., Wang, Z., Fu, Y., Jia, M., Wang, X., Liu, M., Zhang, Y., Sun, Y., Lu, Y., Tang, W., & Yi, F. (2019). PGRN acts as a novel regulator of mitochondrial homeostasis by facilitating mitophagy and mitochondrial biogenesis to prevent podocyte injury in diabetic nephropathy. Cell Death & Disease. https://doi.org/10.1038/s41419-019-1754-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.